PTAB grants BioNTech and Pfizer's inter partes review against Moderna

US Patent Trial and Appeal Board sides with the biotech pair in their challenge against Moderna's mRNA vaccine patents | Inter partes review challenges broad claims and monopolisation over mRNA tech.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Pfizer and BioNTech allege inconsistencies in Moderna’s COVID-19 statements

1 February 2024 Pharma giants raise concerns about Moderna’s COVID-19 vaccine patents | Company's statements to the FDA and PTAB contain "inconsistencies" | Appeals Board urged to scrutinise assertions.

Big Pharma

BioNTech and Pfizer challenge Moderna’s COVID-19 vaccine patent

29 August 2023 Inter partes review challenges broad claims and monopolisation over mRNA tech amidst existing legal dispute | Alnylam set to appeal separate court ruling against Moderna.

Biotechnology

Pfizer faces infringement suit over COVID-19 vaccine

6 April 2023 Arbutus and Genevant claims Pfizer/BioNTech vaccine uses patented technology | Claim follows last year’s lawsuit against Moderna.